Iovance Biotherapeutics Inc (IOVA) News

Based on a number of his posts (and tweets), I wouldn't be surprised if he was a paid social media plant. When NWBO went OTC, they were required to disclose it and have a long history of doing so https://www.nasdaq.com/articles/behind-promotion-northwest-bio-2014-07-07

Spent a little time digesting the call and the transcript. Dr. Gastman was more conservative and obviously holding back a bit as is necessary when discussing trial data for lung. He can't definitively say without requiring an 8-K, but he most certainly implied that the numbers will be acceptable for the BLA which bodes well for us as shareholders.

Mr. Kirby was as expected, confident and focused. Exactly what I want from a CCO. Sales and marketing needed a lot more than they had previously and Kirby does seem like the real deal. It all depends on how effective they are at communicating with new docs, ATCs, and the entire medical teams necessary to start driving earlier referrals of patients. 3rd line+ is not going to cut it and they know that full well. Iovance needs more patients and earlier line patients to really impress and get that exponential growth that I believe is fully possible.

The big takeaway for me is the one we all know, lung is far bigger than the melanoma market, but melanoma is more than enough to be profitable. The slower start did reveal areas that needed attention but are fully correctible for the future success of Iovance. Melanoma was a great place to start and will make future indications pop much quicker upon their approvals now that many of those early bugs are worked out.

For me, the stock market just doesn't want to reward Iovance's past mistakes until some proof is given over the next couple Q's. Believability is still an issue.

End of the year should be bangin'.

GL to IOVA longs.

Bring back the institutional buyers!

https://www.tipranks.com/stocks/iova/forecast

Theorysuit, sorry, but I'm trying to keep off-topic pumping of other companies off this board so I requested removal of the full chain.

Here's hoping we can keep those types of posts to a minimum.

This will get all the bulls excited for years to come.
https://acrobat.adobe.com/id/urn:aaid:sc:VA6C2:8ed05d38-f968-4cc6-a2d7-5db87accc20a

Yeah the shorts keep doubling down. 28%. The only thing is that this company has a lot of connections to hedge funds on their board. WR, PD are both connected. We will see.

Well I jumped in nearly today and am already happy. Caught today's low. If nothing else I see the institutions buying and then shorting when it hits say $8- $10

Looks like another 9 million added to the short interest as of 5/30/25. It's now up to 86 million shares short.

The recent rally with money returning to biotechs will only be helped by the shorts needing to cover some of their positions.

Shorts become the buyers as I continue to add shares. I guess we're competing for those shares.

GL to IOVA longs.

Fireside chat at Goldman Sachs, June 11th, 1:20 pm ET: https://ir.iovance.com/news-releases/news-release-details/iovance-biotherapeutics-present-upcoming-conference

Thanks for the reply!

surfkast, there is no perfect reloading zone. You always seemed to struggle with Iovance and have been nothing but frustrated. This may be one of those companies that you just avoid. It's still going to be bumpy for the coming months and years. Management hasn't demonstrated that they have full control of this process yet, so risk is real and I don't know if your heart can take it.

I'm excited about the science. I'm still adding shares. I believe the company is worth more to most any BP that wants to expand into TIL therapy, but I'm not convinced that the current management team is the best choice for shareholders. It may be time to just get the best offer from BP so that the science can fully flourish even though it would only be a minor gain for most of us who are long shares. I'm fairly confident that the minimum value right now is still in the $4-5 billion range ($12-15/share). Many of my friends and I have average cost of shares below $10. Iovance is certainly worth a lot more once they demonstrate control over the manufacturing process with higher success rates and increasing profit margins. I do believe that they're starting to understand the need to be far more aggressive in their selling and marketing due to the complexities of this process and the challenges in the logistics.

I hate saying this because if they could go it alone, meaning they have a handle on how to grow this company properly and efficiently, IOVA could be a major winner with sales exceeding $2 billion in just a few years, and assuming lung approval down the road, $3-4 billion in sales in maybe less than 5 years. IOVA could get to $40-50/share or more with those kinds of numbers.

But my point remains, IOVA may be a bit too much for you to play anymore. It's not going to be an easy ride even if you're cost per share is around $2.

My attitude, if you're going to trade it, then trade it, but if you're going to invest for the long haul, buy now and walk away for 1 year.

Good luck to the longs.

Did I miss the perfect reloading zone? Do I still jump back in?

It's not that I wanted to sell but I had put some high and I didn't think it would get there and above all that it wouldn't come back! Oh well let's celebrate anyway! I still have some, but if it go down, I'll take back some more!
It's nice when insiders buy with their own money!

I agree with everything you have said. Very thoughtful. Hope you are right for our collective good. Let’s enjoy this beautiful sunny weekend! Cheers Badger🥂

Friday saw a 5+ million share block of IOVA stock trade in the after hours. Any thoughts?

Kirby, the CCO, did buy 30k shares himself in the open market the day prior: https://ir.iovance.com/static-files/20026620-7f04-474c-a36a-f87af3132207

https://ir.iovance.com/sec-filings/sec-filing/4/0001104659-25-057310

Feel free to read the Insider Trading Policy for Iovance (but it still won't guarantee that you'll understand why insiders buy or don't buy): https://www.sec.gov/Archives/edgar/data/1425205/000155837025001834/iova-20241231xex19d1.htm

Sunman, I still don't see the game the same way as you, but we're both taking this ride. I do agree that there were too many missteps and credibility is a hard thing to regain. I'm of the belief that the company is doing the right things now to correct for some of their past mistakes. For both our sakes, I hope I'm right and the company is learning and improving, and that your wrong regarding a plan to take this company private on the cheap.

We're riding together regardless so here's hoping for getting their act together and treating and ultimately helping and healing a great number of patients going forward.

The one thing we share in common is a belief in the science of TIL therapy being a very good option for a vast number of cancer patients.

I certainly hope we're not being played, and fwiw, I don't think we are. I think much of the guidance snafu was due to overzealous expectations that the initial ramp would go close to perfect. Failing to adjust for that overstatement sooner (or not even guiding) is still going to be a tough loss of confidence to overcome. Increasing revenues, margins, and successful new applications can cure a lot of our current concerns most certainly.

GL to us.

One year ago at this time it was at $18. Today, $2 makes you excited and you refer to it as a breakthrough!
The current interim CEO and his top line management team have lost credibility. Share price close to cash says it all. It remains under pressure and the ONLY way out of this mess is a blockbuster Q2 and Q3.
Firing of the CEO has a strong potential to add credibility.
A below par Q2 and Q3 means the end of IOVA for current common shareholders as the thugs would’ve succeeded in handing over the company for a liquidation fire sale for cheap.
Disclosure: I initiated a position at $1.75 and will sell half at $3. Will ride out the rest. Will add a bunch if it breaks $5 on solid lung cancer news and positive news from Amtagvi plus Keytruda trial as it would point to growing demand from the product while the company is learning to reduce COGS.

IOVA BREAKOUT!!

This is a brilliant response thank you! Yes you’re absolutely right it’s involved and time consuming.

jondoeuk, thanks for jumping in. There's just no helping this guy understand that this is an Iovance board. He posts his pretty pictures and graphs, he pumps his company of choice - a company on the verge of financial failure, he insults posters who don't fully agree with his interpretation of the science, and he simply has become a complete waste of time on this board. Some of his posts do get deleted for off-topic and for the equivalent of spam.

Any thoughts on how to educate someone who is so hell bent of causing confusion and spreading misinformation?

Thanks again for your info. Always appreciated.

Good luck to IOVA longs.

See what CYT107 can do?

The poster (click on it to reduce the compression)

Can you show a figure like the following? You have to have a significant number of Tscm cells.

TIL therapy cannot stimulate Tscm cells vital for immune memory.

From one IOVA presentation: ''Our novel TIL expansion process improves multiple metrics that correlate with both TIL persistence and response, including enhanced polyfunctionality, reduced inhibitory receptor expression and a less differentiated and more stem-like phenotype, while increasing yield.'' https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.2542

Can you show me a heatmap like the following from TIL therapy? If you can, I'll stop posting.

Which part of my posts is misinformation? Let IOVA retailers have their own judgements. They can tell if something is BS. By deleting my posts, you deprive them of the opportunity.

I almost hate posting this, but due to continual misinformation and lack of understanding from a certain poster who continually pumps a failing company on this board (Northwest Bio), I share the following AI generated response for clarity (I did not vet all of the info in this brief summary):

"T-cell stem cell memory (TSCM) cells and tumor-infiltrating lymphocytes (TILs) play a crucial role in cancer immunotherapy, particularly in adoptive T-cell therapy. TSCM cells, with their self-renewal and long-term persistence, are valuable for long-lasting anti-tumor immunity, while TILs, which are T cells that have infiltrated a tumor, are a source of tumor-reactive T cells for therapy.
.
TSCM cells are a type of memory T cell with stem-like properties, meaning they can self-renew and generate new T cells. They are characterized by their ability to persist for long periods and maintain their ability to respond to antigens. In cancer immunotherapy, TSCM cells are being explored as a potential source of T cells with superior long-term persistence and anti-tumor efficacy.
.
TIL therapy involves isolating T cells from the tumor microenvironment (TILs), expanding them in the lab, and then reinfusing them into the patient to target cancer cells. TILs are a valuable source of tumor-reactive T cells, as they have already been exposed to the tumor and have developed a specific anti-tumor response.
Relationship between TSCM and TILs:
.
TSCM cells can be present within the tumor and contribute to the pool of TILs. Furthermore, TILs can differentiate into memory T cell subsets, including TSCM, over time. Understanding the relationship between TSCM and TILs is important for designing effective adoptive T-cell therapies, as it may be possible to leverage TSCM cells to enhance the persistence and efficacy of TIL therapy.
Potential Benefits of TSCM in TIL Therapy:
.
By incorporating TSCM cells into TIL therapy, it is possible to enhance the long-term persistence and anti-tumor activity of the infused T cells. This could lead to a more durable anti-tumor response and potentially a higher rate of complete remission.
.
While TSCM and TILs hold promise for cancer immunotherapy, there are challenges to overcome. These include ensuring the T cells persist and do not become exhausted, as well as optimizing the conditions for expansion and reinfusion. Future research will focus on better understanding the factors that influence the differentiation and function of TSCM cells and TILs, as well as developing strategies to enhance their persistence and efficacy in adoptive T-cell therapies."

The future of cancer treatment will be the continual refinements of multiple approaches and optimizing any and all combinations that match best with specific cancer types. It's not one or the other, it's all at the same time and perfecting the match of meds and/or therapies at the best moment in the progression of the disease.

Pumping companies that are on the verge of financial failure like Northwest Bio, even if their science has hope, does not belong on the Iovance board. I don't know why this remains a difficult concept for certain individuals.

GL IOVA longs.

TIL therapy cannot stimulate Tscm cells vital for immune memory. It is not the incompetence of IOVA management that led the landslide of the sp. The true reason is the complete change of the landscape in cancer treatment. If Joseph Edelman is exiting, it doesn't bode well.

It is time consuming and labour intensive, consisting of whole-exome sequencing of DNA, RNA sequencing, creating tandem minigenes, requiring patient-specific monocyte-derived dendritic cells, and selecting the TIL to co-culture with the dendritic cells, before expansion of the neoantigen-reactive TIL. The time from resection to treatment was up to six months, often requiring bridging therapy.

There were a number of correlations with response, including fewer prior lines of therapy, number of neoantigen-reactive CD4+ TIL infused, and the number of neoantigens targeted by the TIL.

A much simpler and quicker method for Iovance would be enriching and expanding PD-1hiCD39+ and/or PD-1+ICOS+ CD4+ T-cells, and building off of that https://insight.jci.org/articles/view/142513 https://www.jci.org/articles/view/156821

Dstock is consistant at bringing little value to this board. Again, resectable vs unresectable, do you honestly not understand what you're posting?

This is all old news, it's always been part of the Iovance story, and regardless the success of these other approaches, Iovance will never have a shortage of patients to treat.

Spend a little more time understanding the science, the differences, the addressable market, and then go post all of that info somewhere else because your constant attempt to mislead on this board has grown tiresome.

You are a time bandit for anyone reading your posts.

GL to IOVA longs.

Another neoadjuvant checking point inhibitor treatment can reduce the number of lung cancer patients who otherwise come to IOVA for the 2nd line treatment.

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer
https://ascopubs.org/doi/pdf/10.1200/JCO-25-00883

Dstock, once again you're confused about the future of cancer treatment. It's a much bigger market that will continually be refined, where treatments will be far better matched to the specifics of each cancer, and where combination therapies will continue to become more commonplace, not less.

I'm glad to hear that you'll never be responding to me again - I feel free like I've never felt before.

This is just one type of neoadjuvant PD1 inhibitor treatment. More will come.

I didn't respond to you first. You replied to my post first.

Here I only talk about neoadjuvant PD1 inhibitor. Once DCVax-L has the approval, IOVA is going to have a hard time for its survival.

Exit this one while you can. This would be my last post to you.

How many patients could potentially benefit from TIL therapy? Does Iovance have the means to support all of them?

There is no shortage of patients for TIL therapy. Iovance has no concerns about all the patients that they won't see, they're focused on all of the patients that will need TIL therapy - which is far more than they will ever be able to handle (sadly).

You post like there's some magic pill out there that will some how eliminate the need for TIL therapy.

The person that doesn't get it is you. You continue to imply that Iovance is somehow going to suffer because some patients (thank goodness) will never need TIL therapy.

You state things that simply aren't true, your conclusions are ludicrous, and frankly, you're nothing more than an obsessive poster with little value offered to the discussion of Iovance and cancer treatment for that matter.

Try thinking before posting next time - and then don't post.

And you told me that you would never respond to me anymore - another post of yours that just wasn't true.

You simply cannot get it, can you?

Amtagvi is the 2nd line treatment, is it not? Neoadjuvant PD1 inhibitor treatment will significantly reduce the number of patients who have to seek the 2nd line treatment. Can you get it now?

Dstock once again doesn't understand what's he's posting. He actually hurts the knowledge base of investors with his incessant nonsense.

"Three cycles of neoadjuvant nivolumab plus chemotherapy significantly improved overall survival among patients with resectable NSCLC as compared with chemotherapy alone."

A resectable cancer by definition can be fully removed by surgery. If successfully removed, the likelihood of positive results following prophylactic treatment or any type of preconditioning with neoadjuvant treatment should be very high. Even without any other type of treatment, if you surgically remove the entire tumor and there's been no spread, the survival results will still be very good. The treatments are done to add a layer of protection just in case.

But here's the problem. What if the tumor is spreading, metastatic, unresectable? When you can show those results on unresectable cancers or metastatic cancers with additional metastases, you'll have something.

That's what TIL therapy can do that all these other treatments cannot do. Iovance is delivering on TIL therapy, and it will continue to be seen as a preferred choice for many types of solid tumor cancers where potential or known spread has occurred, or the tumor is not resectable due to location.

Amtagvi and all future TIL therapies will continue to be the preferred choice for metastatic or unresectable solid tumors. For the record, that's a huge market that we can only hope to catch a small percentage of currently.

GL to IOVA longs.

As a layman, I offer this with the understanding that my explanations may not be perfectly stated, but if anyone who is more skilled in the science wishes to add to this conversation, I'd greatly appreciate it.

Did I remind this board about the competition from neoadjuvant PD1 inhibitor in treating melanoma?

Now the new paper on treating lung cancer with neoadjuvant Opdivo in combination with chemo was published. Read it yourself. Amtagvi is going to have tough competition.

Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
https://www.nejm.org/doi/full/10.1056/NEJMoa2502931

"The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi® (lifileucel) in Patients with Advanced Melanoma"

https://ir.iovance.com/news-releases/news-release-details/journal-clinical-oncology-publishes-five-year-analysis-amtagvir

Thanks for the summary Badger. I agree the science is good and there is bigger potential as more learning occurs.
The current interim CEO and his top line management team have lost credibility. Share price closet cash says it all. it remains under pressure and the ONLY way out of this mess is a blockbuster Q2 and Q3. Firing of the CEO has a strong potential to add credibility.
A below par Q2 and Q3 means the end of IOVA for current common shareholders as the thugs would’ve succeeded in handing over the company for a liquidation fire sale for cheap.

ASCO event with KOL discussion is certainly worth a listen: https://ir.iovance.com/events/event-details/iovance-biotherapeutics-asco-investor-event

I listened to the entire panel discussion and the Q&A. The ASCO KOL panel discussion is worth the time needed to listen, but be aware that onc docs don't get too excited or too negative when discussing the specifics. It's more a matter-of-fact discussion. These guys deal with life and death on a daily basis so it's easy to understand why they don't allow too much emotion into their conversation. Still, based on personal experience with oncologists, they are impressed with Amtagvi and with TIL therapy. The hope is that patients will be treated sooner and appropriate candidates will be identified quicker for earlier treatment. That much was certain.

One key takeaway starts at time stamp 26:40 into the discussion.

For me, an additional key takeaway was that the learning curve was quite a bit more than expected but they are succeeding and improving. The future remains very bright for TIL therapy. All anticipate that other indications will be approved and preparing for that is part of the excitement of improving the systems for treating with Amtagvi at this time, eventually treating other cancer types with TIL therapy in the future.

Expectations are that as ATCs share their experiences, that compilation of information will make it much easier for newer ATCs to get up to speed and have greater success identifying and treating the best candidates with Amtagvi. It will also help improve current active ATCs success rates. The implication is that exponential growth will occur in the coming months and years for Iovance's TIL therapy - something that we've all been waiting for as investors.

They also discussed other possible newcomers to the field, but believed that some of them will be relegated to later line treatments behind the current SOC and TIL therapy as the earlier choices in treating metastatic melanoma and potentially other solid tumors with TIL once additional approvals occur. Though some of the newer potential treatments may seem promising, they just don't offer what TIL therapy has proven over the last 5 years.

One thing was for certain, the logistics of TIL therapy was a bit overwhelming at first for some of the ATCs and docs, but they've got a much better handle on it now and even stated that once up and running, the goal is to not slow down so that the momentum of all that goes into succeeding with TIL therapy doesn't drop off from inactivity. That's where Iovance's chief commercial officer will be most vital, to make sure that outreach and training are optimal.

There will be no shortage of potential patients for Amtagvi, but it's the job of Iovance and their team to ensure that the word gets out, the docs are trained, the ATCs are up to the task, and that the surgeons understand what is necessary to ensure a successful manufacturing of Amtagvi.

Incredible success is there for the taking. The lives of many cancer patients will depend on it.

GL to IOVA longs.

Did you read this news about neoadjuvant immunotherapy on melanoma? Have I repeatedly been alarming you that neoadjuvant immunotherapy alone would significantly reduce the number of patient who other had to seek Lifileucel as the 2nd line treatment?

https://www.asco.org/abstracts-presentations/ABSTRACT487372

Presented at ASCO 2025 - 5 year results impressive: https://meetings.asco.org/abstracts-presentations/244155

Study for combo with Pembro for nsclc - results solid, approval should follow assuming numbers hold: "Tumor-infiltrating lymphocyte (TIL) therapy with lifileucel plus pembrolizumab (pembro) demonstrated durable and deepening responses with an objective response rate (ORR) of 64.3%..." https://meetings.asco.org/abstracts-presentations/252559

Updated results from IOV-COM-202 Cohort 1A (Lifileucel plus Keytruda) shows an ORR of 65.2% (CR rate 30.4%). The mDOR was not reached https://ir.iovance.com/static-files/6e77db81-ba69-4c07-a092-797d83ac5bcb

ASCO Investor Event tonight, May 31st: https://ir.iovance.com/events/event-details/iovance-biotherapeutics-asco-investor-event

theorysuit, Agree with your statement below, but you posted it on a WRONG board!!!

>>>>>>theorysuit
Re: martyDg post# 769868

Friday, May 30, 2025 8:33:23 PM

>>>>>This is textbook definition of a scam. They even got paid pumps galore that apologize and make up BS excuses and pump all kind of nonsensical carrots.>>>>>>

theorysuit - this thing needs activated DC to work. !!!

Just think, FDA approval for melanoma a year ago & since SP has DROPPED BY ABOUT 90%..

P.S. trash posting on other boards won't help you!!!

Approval will come sooner or later. The longs have the patience. 1.9 billion shares is not a big deal. Cannot you see Merck lost over $110b last year?

You must have been brainwashed by Fraudstein. Do you know the percentage of pseudoprogression for patients receiving CI? It is very rare and the percentage is less than 10%. Pseudoprogression means significant t-cell infiltration into tumor sites that causes swollen tissue. Those t-cells come to tumor site to eliminate cancer cells. What's the occurrence rate of pseudoprogression in the p3 trial? Over 30%! This means over 30% patients had significant t-cell infiltration into the most difficult and coldest tumor to eliminate cancer cells. It also means all those checking point inhibitors like keytruda which can only work under the condition that t-cells have to be present in tumor site in the first place can boost the anti-tumor immune response. Get it!

I don't do dot connecting. It is too childish. I only do data analysis and let data guide me. Data analysis let me know Merck's deal with Daiichi is about CSF1R inhibitor. Data analysis pointed me that the UK Specials Program has been including poly-iclc. Data analysis enlightened me that the TLR agonist mentioned in 10K is not about TLR3 from Oncovir but about TLR4 from Merck. Data analysis told me exactly when the paper on the trial sponsored by Merck would be published.
Data analysis also delivered the correct prediction about IOVA's sp since it was $20.



https://www.nature.com/articles/s41467-024-54326-7

Do you have any idea why nwbo's pivotal trial ended in 2018 and here we are in mid 2025 and they still have no approvals? Does science have an answer for that? It is called a scam. Lmfao at that joke of a company. Why does the ceo own the company funded cdmo? Does science have an answer for that too? Again scam. Yes I get you are a paid company pump.......that's why they dilute on a daily basis and have an absurd 1.9 billion shares authorized.

If you can refute any of these business facts, please feel free to provide a counter argument. A cure? Have you checked the original pfs endpoint of nwbo's trial....utter failure. That's why they tried to pivot endpoints and also make up their placebo. That isn't proper science. You announce failure and design a proper trial. But keep posting non relevant charts, articles and nonsensical dot connecting speculating the Big pharma is operating for nwbo.

ASCO Investor Event tomorrow, May 31st: https://ir.iovance.com/events/event-details/iovance-biotherapeutics-asco-investor-event